322 related articles for article (PubMed ID: 9038292)
1. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.
Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC
Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292
[TBL] [Abstract][Full Text] [Related]
2. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.
Chang YF; Appel MJ; Jacobson RH; Shin SJ; Harpending P; Straubinger R; Patrican LA; Mohammed H; Summers BA
Infect Immun; 1995 Sep; 63(9):3543-9. PubMed ID: 7642289
[TBL] [Abstract][Full Text] [Related]
3. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies.
Kurtenbach K; Dizij A; Voet P; Hauser P; Simon MM
Vaccine; 1997 Oct; 15(15):1670-4. PubMed ID: 9364698
[TBL] [Abstract][Full Text] [Related]
5. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2.
Johnson BJ; Sviat SL; Happ CM; Dunn JJ; Frantz JC; Mayer LW; Piesman J
Vaccine; 1995 Aug; 13(12):1086-94. PubMed ID: 7491816
[TBL] [Abstract][Full Text] [Related]
6. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites.
Gern L; Rais O; Capiau C; Hauser P; Lobet Y; Simoen E; Voet P; PĂȘtre J
Immunol Lett; 1994 Mar; 39(3):249-58. PubMed ID: 8034340
[TBL] [Abstract][Full Text] [Related]
7. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
Scheckelhoff MR; Telford SR; Hu LT
Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
[TBL] [Abstract][Full Text] [Related]
8. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.
Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E
Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses.
Chang Y; Novosol V; McDonough SP; Chang CF; Jacobson RH; Divers T; Quimby FW; Shin S; Lein DH
Vaccine; 1999 Oct; 18(5-6):540-8. PubMed ID: 10519945
[TBL] [Abstract][Full Text] [Related]
10. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.
Luke CJ; Huebner RC; Kasmiersky V; Barbour AG
Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476
[TBL] [Abstract][Full Text] [Related]
11. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
12. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
[TBL] [Abstract][Full Text] [Related]
14. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection.
Zhong W; Gern L; Kramer M; Wallich R; Simon MM
Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822
[TBL] [Abstract][Full Text] [Related]
15. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
16. Vaccination as a modality to prevent Lyme disease. A status report.
Wormser GP
Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796
[TBL] [Abstract][Full Text] [Related]
17. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.
Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P
J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA
PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
Grosenbaugh DA; Rissi DR; Krimer PM
Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]